Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization. Stifel initiated coverage of Roivant with a Buy rating and a $51 price target on September 16. The target implied a roughly 29% upside from the stock price at that time.
Stifel argued that Roivant offers multiple late-stage opportunities across specialty autoimmune and pulmonary diseases. The firm projects around $9 billion in ownership-adjusted sales for Roivant by 2037. Can Roivant turn its multi-asset strategy into long-term revenue growth?
Roivant Sciences Ltd. (NASDAQ:ROIV)'s most immediate opportunity is Lisraya (brepocitinib). The FDA approved Lisraya on August 27 for adults with dermatomyositis. The drug became the first FDA-approved oral treatment for the rare disease.
Roivant sees potential in brepocitinib beyond its initial indication for adults with dermatomyositis. The compound is being evaluated in non-infectious uveitis, and Roivant expects topline data from a Phase 3 study in the second half of 2026. Roivant is also evaluating brepocitinib in cutaneous sarcoidosis and lichen planopilaris.
Phase 3 data from the cutaneous sarcoidosis study is expected in 2028. Meanwhile, enrollment in Part 1 of a Phase 2b/3 study of the compound in lichen planopilaris is on course. The Lisraya approval provides a fresh test of Roivant's commercial execution as the company seeks to translate another clinical success into meaningful revenue.
The drug's approval alone does not guarantee rapid adoption. Considering that Lisraya targets a rare disease, physician awareness, reimbursement, and competition will influence the pace of its uptake. Beyond brepocitinib (Lisraya), Roivant Sciences Ltd. (NASDAQ:ROIV) has a broad pipeline targeting multiple disease areas.
Extract — continue reading at the source.
